Pipeline › retatrutide

retatrutide

Not FDA-approved, and in phase 3 development, not authorised in the European Union. 7 active trials, the next due to complete 2026-10.

GIP/GLP-1/glucagon agonist, SC, from Eli Lilly. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.

Status: phase3
Target: GIP/GLP-1/glucagon
Route: SC
Sponsor: Eli Lilly
First FDA approval: Not approved
EU authorisation: Not authorised
Active trials: 7 (6 in phase 3)
Participants enrolled: 12,699
Trials with a reporting date: 7
Approved FDA submissions: 0

When these trials report

When trials are due to report, by quarter — hover a bar for the count. These dates are filed by the sponsor and often move.

Next 7 of 7 active trials by estimated primary completion.

Est. completion	Trial	Sponsor	Phase	Participants
2026-10	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) NCT06297603 · Change from Baseline in Hemoglobin A1c (HbA1c) (%)	Eli Lilly and Company	P3	320
2027-03-14	Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight NCT07467447 · Mean percent change in body weight from randomization/baseline to Week 24.	Hudson Biotech	P2	300
2027-07	A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight NCT07232719 · Percent Change from Baseline in Body Weight	Eli Lilly and Company	P3	250
2027-09	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain NCT07035093 · Change from Baseline in Pain Intensity Per Numeric Rating Scale	Eli Lilly and Company	P3	586
2028-04	A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity NCT06859268 · Percent Change from Baseline in Body Weight	Eli Lilly and Company	P3	643
2028-10	A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight NCT07357415 · Percent Change from Baseline in Body Weight	Eli Lilly and Company	P3	600
2029-02	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) NCT06383390 · Time to First Occurrence of Composite Endpoints	Eli Lilly and Company	P3	10,000

Indications under study

Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD); Chronic Low Back Pain (CLBP); Obesity; Overweight; Type 2 Diabetes.

Recent papers

Published	Title	Journal
2026-09-01	Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia Piatkowski T, Craven A, Cornell S, Ferris J.	Drug Alcohol Rev
2026-08-26	Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis Branine N.	Cureus
2026-08-17	Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ.	Diabetes Obes Metab
2026-08-07	Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it Brown C.	BMJ
2026-08-01	Retatrutide effects on diabetic rats' cognition Ferreira J.	Lab Anim (NY)
2026-07-23	Retatrutide and the urinary tract infection signal: Is the answer hidden in timing? Koufakis T, Argyrakopoulou G, Kokkinos A, le Roux CW.	Eur J Intern Med
2026-07-09	Retatrutide fact check: Has a man died after taking the unapproved weight loss jab? Mahase E.	BMJ
2026-07-01	Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats Keskin U, Altın E, Kara MK, Tekin B, Çakırçoban KN, Özatik FY, Arı NS, Sezgin AK, Güngor E.	Behav Brain Res
2026-06-29	Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V.	High Blood Press Cardiovasc Prev
2026-06-09	Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports Lang K.	BMJ
2026-06-06	Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A.	Lancet
2026-06-01	A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide Mao CY, Pang ZJ, Qiao GY, Dong L.	Org Lett
2026-05-14	Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes Pearson MJ, Willency JA, Lin Y, Abadi A, Hartman ML, Coskun T, Ruotolo G, Duffin KL, Haupt A, Newgard CB, Pirro V.	J Clin Endocrinol Metab
2026-05-11	Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review Pillai AA, Godin SL, Frishman WH, Aronow WS.	Cardiol Rev
2026-05-01	Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L.	Nephrol Dial Transplant

Headlines

2026-09-03

FDA Criticized for Inaction as Black Market for Unapproved Weight-Loss Drug Retatrutide Flourishes Online

citybuzz.co

2026-09-03

Everything you need to know about the weight-loss drug retatrutide, according to experts

British GQ

2026-08-25

'Gray Market' Retatrutide Study; Menopause and the Brain; Drug Allergy Warnings

MedPage Today: endocrinology

Get the briefing

retatrutide

When these trials report

Indications under study

Recent papers

Headlines

Related